Fig. 1From: Cardiovascular toxicities after anthracycline and VEGF-targeted therapies in adolescent and young adult cancer survivorsCumulative incidence of any cardiovascular toxicity by therapy received: (A) Anthracycline only (B) VEGF inhibitor only (C) Anthracycline and VEGF inhibitorBack to article page